Emerging Infectious Disease Diagnostics Market Forecast 2025-2034: Analysing Major Trends, Opportunities, and Growth Drivers

What combination of drivers is leading to accelerated growth in the emerging infectious disease diagnostics market?
The escalating prevalence of diseases transmittable from animals to humans, known as zoonotic diseases, anticipates boosting the expansion of the emerging infectious disease diagnostics market in the future. The key reasons for this upsurge include amplified interplay between humans and wildlife, the destruction of animal habitats, and worldwide travel, enabling cross-species transmission of pathogens. Spot-on identification of pathogens and early detection is made possible by emerging infectious disease diagnostics, contributing to swift interference, efficacious treatment, and improved control of disease flare-ups, thus minimizing the transfer of diseases from animals to humans. For example, the 2022 Zoonotic Disease Report from the US-based State of West Virginia government administration outlined in the MMWR Year 2022 showed an increase in reported Lyme disease cases, from 1,788 in 2021 to 2,449 in February 2024. Consequently, the growing prevalence of zoonotic diseases propels the emerging infectious disease diagnostics market.

Get Your Emerging Infectious Disease Diagnostics Market Report Here:
https://www.thebusinessresearchcompany.com/report/emerging-infectious-disease-diagnostics-global-market-report

What is the projected compound annual growth rate (CAGR) of the emerging infectious disease diagnostics market from 2025 to 2034, and what factors influence it?
In recent years, the market size for emerging infectious disease diagnostics has seen robust growth. The market, which was valued at $22.13 billion in 2024, is projected to increase to $24.34 billion in 2025 with a compound annual growth rate (CAGR) of 10.0%. Factors contributing to this growth during the historical period include the growing demand for point-of-care diagnostics, the escalating prevalence of infectious diseases, an increase in global population density, a rise in the occurrence of infectious diseases, and a surge in healthcare spending.

In the forthcoming years, it is anticipated that the emerging infectious disease diagnostics market will experience robust growth, with size projections surmounting to $35.21 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. Factors contributing to this progression in the forecasted period include the escalating prevalence of zoonotic diseases, notable progress in regulatory reforms and assistance, advancements in universal vaccine development, an intensified focus on the one health approach, and increased government backing and financing. Noteworthy trends during this forecast period encompass technological breakthroughs, next-generation sequencing (NGS), isothermal amplification methodologies, telemedicine merged with remote diagnostics, and environmental pathogen tracking.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20548&type=smp

How are the latest trends influencing the growth of the emerging infectious disease diagnostics market?
Leading organizations in the emerging infectious disease diagnostics market are setting their sights on innovative technologies, specifically molecular diagnostic systems, to maintain a competitive edge. These platforms employ nucleic acid amplification techniques for pathogen detection, boasting high sensitivity and specificity, making accurate and early discovery possible. For example, in May 2022, a US-based medical equipment manufacturer called Becton Dickinson and Company unveiled the BD COR MX/PX System, a fully automated diagnostic platform that allows for high-volume throughput. This progressive system enhances lab productivity by automating the entire molecular process, from processing of samples to the delivery of results. The inaugural assay, the BD CTGCTV2, screens for three prevalent non-viral sexually transmitted infections (STIs). The BD COR MX/PX System is capable of processing a maximum of 1,700 specimens with reagents and samples onboard, allowing for over seven hours of continual use and providing up to 1,000 results in a day, significantly diminishing manual processing for lab technicians.

What are the major segments of the emerging infectious disease diagnostics market and their role in driving growth?
The emerging infectious disease diagnostics market covered in this report is segmented -

1) By Infection Type: Viral, Bacterial, Fungal, Other Infections
2) By Disease Type: Respiratory Infections, Gastrointestinal Infections, Sexually Transmitted Infections (STIs), Other Disease Types
3) By Technology: Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), Next-Generation Sequencing (NGS), Immunodiagnostics, Other Technologies
4) By Application: Laboratory Testing, Point-of-Care Testing
5) By End-User: Hospitals And Clinics, Diagnostics Laboratories, Other End-Users

Subsegments:
1) By Viral: Respiratory Viruses, Hepatitis Viruses, HIV and Retroviruses, Arboviruses, Herpesviruses, Gastrointestinal Viruses, Emerging Viral Infections
2) By Bacterial: Tuberculosis (TB), Methicillin-Resistant Staphylococcus Aureus (MRSA), Escherichia Coli (E. coli) Infections, Streptococcus and Pneumococcus Infections, Clostridium Infections, Neisseria, Emerging Drug-Resistant Bacteria
3) By Fungal: Candidiasis, Aspergillosis, Cryptococcosis, Histoplasmosis, Coccidioidomycosis, Pneumocystis Pneumonia (PCP), Emerging Fungal Infections
4) By Other Infections: Parasitic Infections, Protozoan Infections, Prion Diseases, Helminthic Infections, Non-Pathogenic or Environmental Infections

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20548

Which regions are key players in the growth of the emerging infectious disease diagnostics market?
North America was the largest region in the emerging infectious disease diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the emerging infectious disease diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the key firms paving the way for growth in the emerging infectious disease diagnostics market?
Major companies operating in the emerging infectious disease diagnostics market are Roche Diagnostics, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers, Becton Dickinson and Company, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Hologic Inc., Illumina Inc., bioMérieux SA, QuidelOrtho Corporation, Bio-Rad Laboratories, Inc., Qiagen N.V., DiaSorin S.p.A., Randox Laboratories Ltd., Meridian Bioscience Inc., Sekisui Diagnostics LLC, Copan Diagnostics, Co-Diagnostics Inc., T2 Biosystems Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=20548&type=smp

What Is Covered In The Emerging Infectious Disease Diagnostics Global Market Report?

•Market Size Forecast: Examine the emerging infectious disease diagnostics market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the emerging infectious disease diagnostics market for a structured understanding.
•Key Players Overview: Analyze major players in the emerging infectious disease diagnostics market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the emerging infectious disease diagnostics market.
•Segment Contributions: Evaluate how different segments drive overall growth in the emerging infectious disease diagnostics market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the emerging infectious disease diagnostics market.
•Industry Challenges: Identify potential risks and obstacles affecting the emerging infectious disease diagnostics market.
•Competitive Landscape: Review strategic developments in the emerging infectious disease diagnostics market, including expansions, agreements, and new product launches.

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.